Abandoning the Notion of Non-Small Cell Lung Cancer
- PMID: 31155338
- DOI: 10.1016/j.molmed.2019.04.012
Abandoning the Notion of Non-Small Cell Lung Cancer
Abstract
Non-small cell lung cancers (NSCLCs) represent 85% of lung tumors. NSCLCs encompass multiple cancer types, such as adenocarcinomas (LUADs), squamous cell cancers (LUSCs), and large cell cancers. Among them, LUADs and LUSCs are the largest NSCLC subgroups. LUADs and LUSCs appear sharply distinct at the transcriptomic level, as well as for cellular control networks. LUADs show distinct genetic drivers and divergent prognostic profiles versus LUSCs. Therapeutic clinical trials in NSCLC indicate differential LUAD versus LUSC response to treatments. Hence, LUAD and LUSC appear to be vastly distinct diseases at the molecular, pathological, and clinical level. Abandoning the notion of NSCLC may critically help in developing novel, more effective subtype-specific molecular alteration-targeted therapeutic procedures.
Keywords: lung cancer; prognosis; therapy; tumor classification.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050. J Natl Compr Canc Netw. 2017. PMID: 28404761
-
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.Lung Cancer. 2019 Aug;134:108-116. doi: 10.1016/j.lungcan.2019.05.034. Epub 2019 May 31. Lung Cancer. 2019. PMID: 31319968
-
[Non-small cell lung cancer. New biomarkers for diagnostics and therapy].Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1. Pathologe. 2015. PMID: 26391246 Review. German.
-
Prognostic alternative mRNA splicing signature in non-small cell lung cancer.Cancer Lett. 2017 May 1;393:40-51. doi: 10.1016/j.canlet.2017.02.016. Epub 2017 Feb 20. Cancer Lett. 2017. PMID: 28223168
-
Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.J Huazhong Univ Sci Technolog Med Sci. 2016 Jun;36(3):321-327. doi: 10.1007/s11596-016-1586-7. Epub 2016 Jul 5. J Huazhong Univ Sci Technolog Med Sci. 2016. PMID: 27376798 Review.
Cited by
-
Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241282080. doi: 10.1177/15330338241282080. Technol Cancer Res Treat. 2024. PMID: 39360506 Free PMC article.
-
Construction and Validation of Prognosis Nomogram for Metastatic Lung Squamous Cell Carcinoma: A Population-Based Study.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221132035. doi: 10.1177/15330338221132035. Technol Cancer Res Treat. 2022. PMID: 36217877 Free PMC article.
-
Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis.Genomics Proteomics Bioinformatics. 2022 Oct;20(5):850-866. doi: 10.1016/j.gpb.2022.11.003. Epub 2022 Dec 1. Genomics Proteomics Bioinformatics. 2022. PMID: 36462630 Free PMC article. Review.
-
Prognostic markers of ferroptosis-related long non-coding RNA in lung adenocarcinomas.Front Genet. 2023 Feb 27;14:1118273. doi: 10.3389/fgene.2023.1118273. eCollection 2023. Front Genet. 2023. PMID: 36923797 Free PMC article.
-
Overexpression of abnormal spindle-like microcephaly-associated (ASPM) increases tumor aggressiveness and predicts poor outcome in patients with lung adenocarcinoma.Transl Cancer Res. 2021 Feb;10(2):983-997. doi: 10.21037/tcr-20-2570. Transl Cancer Res. 2021. PMID: 35116426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
